INTRODUCTION: Biologics, which are monoclonal antibodies targeting molecular intermediates, provide a promising therapy for severe asthmatics. Thus, biologics have quickly become integrated into the treatment regimen of severe asthma. However, there is limited knowledge of the pattern of use of biologic therapy in current clinical practice (i.e. continue, stop, switch) and the characteristics underpinning these patterns. This study thus aimed to explore baseline clinical and demographic characteristics of a real-life severe asthma cohort according to pattern of biologic use.
|Conference||Respiratory Effectiveness Group Summit 2020|
|Period||19/03/20 → 21/03/20|